Abstract:
Ten cases of adult T-cell leukemia-lymphoma (ATL/L) in the Hokuriku district were studied. Five patients were born in endemic areas and later moved to Hokuriku. Five patients were from nonendemic areas, and have not lived in endemic areas. All of the five patients from nonendemic areas had antibody to the adult T-cell leukemia cell-associated antigen (anti-ATLA), and they had anti-ATLA-positive members in their families. Four of the six patients examined had ATL virus (ATLV) proviral DNA in their leukemic cells and type C virus particles were found in the cultured cell line from one of them (case S.D.). The incidence of anti-ATLA in the control population was 0.93% in Ishikawa Prefecture, 0.39% in Toyama Prefecture and 0% in Fukui Prefecture. The overall positive rate in the controls in Hokuriku was 0.49%. The rate of positive anti-ATLA among family members of seven ATL patients (patients are excluded) was 43.5% (17/39). The pedigree study of ATL patients very strongly suggested transmission of ATLV between spouses and transmission from mother to children. We also report a case of ATL from an endemic area, who has been in remission without antileukemic therapy for about one year. He is on 5 FC (5-fluorocytosine), Minomycin (minocycline hydrochloride), and Baktar (trimethoprim-sulfamethoxazole). Possibility that the therapeutic effect of 5 FC on ATL or the remission is due to enhanced cellular immunity after cryptococcus infection is discussed.
Keywords: Adult Aged Antibodies, Neoplasm/ANALYSIS Case Report Cryptococcosis/*IMMUNOLOGY DNA, Viral/ANALYSIS Female Genes, Viral Human HTLV-BLV Viruses/GENETICS Japan Leukemia/DRUG THERAPY/EPIDEMIOLOGY/*IMMUNOLOGY Lymphoma/DRUG THERAPY/EPIDEMIOLOGY/*IMMUNOLOGY Male Middle Age T-Lymphocytes JOURNAL ARTICLE
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
